Brewer Science (Rolla, Missouri), a global leader in developing and manufacturing next-generation materials and processes for the microelectronics and optoelectronics industries, recently announced the appointment of Ken Joyce as executive vice president. In his new role, Joyce will lead Brewer Science’s efforts to identify, pursue and execute strategic growth alternatives to further accelerate the company’s long-term, global growth.
E Ink Holdings (Billerica, Massachusetts), a leading innovator of electronic ink technology, Wacom, the world’s leading manufacturer of pen tablets, interactive pen displays and digital interface solutions, and Linfiny, a joint development between E Ink and Sony Semiconductor Solutions, recently announced their next-generation Digital Paper solutions. These solutions feature Wacom’s EMR technology, which provides greater accuracy, with 4096 pressure sensitivity and support for faster pen speeds. Offered in a 10.3” and a 13.3” size, the new solutions feature a higher contrast ratio and faster page turns, through the use of the latest E Ink Carta 1250, and improvements in pen writing speed and an enhanced user interface for application offerings. Linfiny has worked closely with E Ink over the past three years to integrate the newest Carta ink and tuning the visual performances into the solution to bring the full benefits of the new film to the device.
During clinical trials of new drugs pharmaceutical companies must be able to depend on strict adherence to therapy regimens. However, up to 50 percent of patients involved in clinical trials do not adhere to the prescribed dosage regimen, resulting in distorted outcomes such as insufficient drug efficacy or underestimated frequency of side effects and delayed time to market. To enhance therapy adherence in clinical trials, Schreiner MediPharm (Oberschleißheim, Germany) and AARDEX Group (Seraing, Belgium) offer an electronic solution for medication adherence monitoring enabling pharmaceutical companies to digitally monitor and manage medication intake of their trial participants.
